MedTrace Logo

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

NCT01923389 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2014-09-17

Study results available
· View outcomes & findings →

Summary

This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

OTHER

Placebo

0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.

DRUG

100 mg PF-05231023

100 mg IV infusion twice a week for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01923389 on ClinicalTrials.gov